In light of these findings, we aimed to explored the relationship between mTOR/eIF4E activation and immunotherapy response in an EBV‐positive GC cohort, which contains 16 patients received induction chemotherapy combined with anti‐PD‐1 immunotherapy before surgical resection. Here, EIF4E is linked to gastric cancer.